60 results on '"Tummala, Raj"'
Search Results
2. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
3. LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
4. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature
5. Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study
6. Targeting DORIS Remission and LLDAS in SLE: A Review
7. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
8. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
9. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
10. Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
11. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
12. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
13. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
14. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
15. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
16. Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
17. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
18. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
19. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
20. Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
21. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
22. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
23. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis
24. 1401 Effects of anifrolumab on renal disease in patients with systemic lupus erythematosus
25. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases
26. What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
27. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
28. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
29. Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
30. Exposure–response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus
31. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
32. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
33. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
34. Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature
35. O25 Efficacy of anifrolumab in active systemic lupus erythematosus (SLE): patient subgroup analysis of BICLA response in 2 phase 3 trials
36. O24 Flare assessments in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab in 2 phase 3 trials
37. P186 Early and sustained responses with anifrolumab in patients with systemic lupus erythematosus (SLE) in 2 phase 3 trials
38. Trial of Anifrolumab in Active Systemic Lupus Erythematosus
39. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
40. OP0128 SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE CHARACTERISTICS ASSOCIATED WITH THE TYPE I INTERFERON GENE SIGNATURE: BASELINE DATA OF THE SLE PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)
41. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
42. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
43. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
44. Response to: ‘Comment on: ‘Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al’ by Isenberg
45. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation
46. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
47. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
48. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation
49. Content validity of the Sheehan Irritability Scale in patients with major depressive disorder
50. Efficacy and safety of naloxegol in patients with opioid‐induced constipation and laxative‐inadequate response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.